Global and United States Alpha 1 Antitrypsin Deficiency Treatment Market Report & Forecast 2022-2028

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
Market Analysis and Insights: Global and United States Alpha 1 Antitrypsin Deficiency Treatment Market
This report focuses on global and United States Alpha 1 Antitrypsin Deficiency Treatment market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Alpha 1 Antitrypsin Deficiency Treatment market size is estimated to be worth US$ 2042.3 million in 2022 and is forecast to a readjusted size of US$ 3425.1 million by 2028 with a CAGR of 9.0% during the review period. Fully considering the economic change by this health crisis, by Indication, Augmentation Therapy accounting for % of the Alpha 1 Antitrypsin Deficiency Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by End Users, COPD was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.
Global Alpha 1 Antitrypsin Deficiency Treatment Scope and Market Size
Alpha 1 Antitrypsin Deficiency Treatment market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Alpha 1 Antitrypsin Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Alpha 1 Antitrypsin Deficiency Treatment market size by players, by Indication and by End Users, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Indication
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Segment by End Users
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences